From the onset of the novel coronavirus outbreak, QIAGEN’s dedicated global teams have been working around the clock to ensure the availability of existing testing solutions and to develop new SARS-CoV-2 tests to address international testing needs. We have dramatically scaled up production, moving to 24 hour, seven-day-a-week operations at our manufacturing sites, and are investing in additional equipment capacity. Today, we offer the most comprehensive portfolio of SARS-CoV-2 testing solutions on the market, covering the needs of clinical and research customers, from manual to automated sample processing, low to high throughput, single-plex to multi-plex, and from active infection testing to the detection of previous viral exposure.
Background information on QIAGEN solutions, the coronavirus, and how coronavirus testing works available here (Updated September 18th).
Featured
-
Suppliers behind the front lines of COVID-19Suppliers find novel ways to motivate while working long hours to up the supply of components necessary for coronavirus testing kits. -
Ensuring critical deliveries when every minute countsUPS teams up with QIAGEN to deliver coronavirus testing solutions to curb the COVID-19 pandemic. -
Host immune response to COVID-19 webinarVirologist researchers use QIAGEN Digital Insights solutions to identify coronavirus fusion and immune control.
Latest news
-
September 17, 2020QIAGEN fully takes over NeuMoDx Molecular, Inc. to round out diagnostic instruments portfolio.
-
September 8, 2020QIAGEN to launch rapid portable test that can analyze over 30 samples per hour for SARS-CoV-2 antigen.
-
August 18, 2020QIAGEN expands integrated coronavirus NGS and software solutions to accelerate COVID-19 research
Samples of QIAGEN in the Media
-
MSNBCNBC’s Richard Engel covers the development of new coronavirus test kits at QIAGEN and how the company has been ramping up production to meet demand. -
CNNThierry Bernard explains the development of the coronavirus test and QIAGEN’s work to scale up testing capacity in a live CNN interview. -
NBCInside coronavirus testing labs amid shortage fears: NBC covers QIAGEN seeking fast FDA approval for the QIAstat-Dx test that provides results in about an hour.
Emergency protocols
Supporting healthcare workers around the world in the fight against COVID-19
QIAGEN supports several testing protocols by providing test components, mid- to high-throughput automation solutions, and a multiplex syndromic detection solution. We also support scientists seeking to better understand the SARS-CoV-2 virus with research tools, including sequencing components and tools for data analysis and interpretation. We will continue to work tirelessly on novel approaches.
QIAGEN support in current testing protocols for emergency use
CDC 2019-nCoV RT-PCR Diagnostic Panel
- QIAamp Viral RNA Mini Kit
- QIAamp DSP Viral RNA Mini Kit (Limited country availability, incl. US, S. Korea & China)
- EZ1 DSP Virus Kit (Canada, USA)
- EZ1 DSP Virus Kit (other countries)
- EZ1 Virus Mini Kit 2.0
- EZ1 Advanced XL
- QIAcube
Testing
RNA extraction
Given the current public health emergency with COVID-19, QIAGEN and other companies are facing unprecedented demand for viral RNA isolation solutions. QIAGEN has developed dedicated solutions for viral RNA isolation that have been optimized for maximum sensitivity and reproducibility. We recognize that currently, scientists are seeking to use various QIAGEN kits, such as RNeasy, for SARS-CoV-2 RNA isolation from respiratory samples. It is critical to note that these kits have not been designed for isolating viral RNA, and performance of each kit varies. The user must consult the product-specific handbook or user manual. We strongly recommend using only dedicated RNA isolation products for SARS-CoV-2, such as those listed below:
Solutions authorized for use for COVID-19 testing in some regions (please check local regulations)
- QIAamp Viral RNA Mini Kit (250). This spin column product can be used manually or operated on the QIAcube.
- QIAsymphony DSP Virus/Pathogen Mini or Midi Kits. These products are operated on the QIAsymphony platform.
- EZ1 DSP Virus Kit (48), available in US/Canada and other countries, or EZ1 Virus Mini Kit v2.0 (48). These are pre-configured kits that are operated on the EZ1 Advanced XL.
- QIAamp DSP Viral RNA Mini Kit (50). This spin column product can be used manually or operated on the QIAcube (limited country availability, incl. US, S. Korea and China).
Research solutions
- QIAamp Viral RNA Mini Kit (250). This spin column product can be used manually or operated on the QIAcube Connect or QIAcube.
- QIAamp 96 Virus QIAcube HT Kit (5). This product consists of 5 × 96 well plates to be operated on the QIAcube HT.
- QIAamp MinElute Virus Spin Kit (50). This spin column product can be used manually or operated on the QIAcube Connect or QIAcube.
Antibody testing
Access Anti-SARS-CoV-2 Total Test
To enable accessible and accurate SARS-CoV-2 antibody testing, QIAGEN now offers the Access Anti-SARS-CoV-2 Total Test (Anti-CoV2). The Anti-CoV2 test enables rapid, qualitative detection of total antibodies to SARS-CoV-2. Features include Total Ig detection (IgA, IgM, and IgG), results in approximately 10 minutes, and the ability to test up to 8 patients simultaneously on the digital Access eHub.
- Access Anti-SARS-CoV-2 Total Test (available in the US, test not reviewed by the FDA)
Syndromic Testing
QIAGEN multiplex syndromic testing support for SARS-CoV-2*
To support the efforts for accessible testing to meet the demands of the COVID-19 outbreak, QIAGEN has developed the QIAstat-Dx Respiratory SARS-CoV-2 Panel. This version of our multiplex syndromic cartridge enables detection of the SARS-CoV-2 virus that causes COVID-19 in addition to 20+ other respiratory pathogens.*
- QIAstat-Dx Respiratory SARS-CoV-2 Panel (available in the US, under Emergency Use Authorization only)
- QIAstat-Dx Respiratory SARS-CoV-2 Panel (available in limited countries)
Targeted PCR Testing
NeuMoDx Systems
The NeuMoDx 96 and NeuMoDx 288 systems offer a rapid and fully automated PCR test for the detection of SARS-CoV-2, under FDA Emergency Use Authorization, that can deliver a result within an hour. A new multiplex test for influenza, respiratory syncytial virus (RSV) and the SARS-CoV-2 virus is scheduled for launch in the fourth quarter of this year. NeuMoDx systems provide an ideal solution for hospitals or central testing labs, delivering the speed and flexibility to support the large numbers of patient samples they receive.NeuMoDx 96 and NeuMoDx 288 Systems.
Tailored oligonucleotides for SARS-CoV-2 detection
Updated April 27
In our effort to support the detection of the SARS-CoV-2 virus, OEM by QIAGEN has ramped up the production of SARS-CoV-2 specific primers and probes. We provide customized oligos defined by our customers, as well as those mentioned in protocols recommended by WHO and the CDC. To meet the high demands, we are currently prioritizing the orders of SARS-CoV-2 specific oligonucleotides. In addition, we have introduced pre-manufacturing of these oligonucleotides to enable quick supply and delivery. To order, please send your requests here.
Learn more about OEM by QIAGEN.
Research
NGS resources for coronavirus molecular epidemiology, vaccine development and drug discovery research
The new QIAseq SARS-CoV-2 Primer Panel enables targeted enrichment and deep sequencing of the complete SARS-CoV-2 genome. With a single-day workflow, and the ability to multiplex up to 384 samples when combined with the QIAseq FX DNA Library UDI Kit, this NGS panel provides faster results – with lower input requirements – compared with hybrid capture approaches. Rapid sequence and phylogenetic data analysis are also available using pre-built and optimized pipelines in the QIAGEN CLC Genomics Workbench. Obtain a trial kit of the QIAseq SARS-CoV-2 Primer Panel and learn more about the complete solution here.
Whole Genome Sequencing Services
QIAGEN Genomic Services provides a comprehensive Sample-to-Insight SARS-CoV-2 Whole Genome Sequencing Services to support your research. Whether you’re studying strain evolution or performing phylogeographic or metagenomic analyses, Genomic Services is the right partner for providing impactful insights and helping accelerate your COVID-19 research. This service uses technology especially designed for SARS-CoV-2 research.
Bioinformatics analysis of SARS-CoV-2 with QIAGEN Digital Insights
To support the efforts of clinical microbiology and public health laboratories involved in SARS-CoV-2 sequencing, QIAGEN is offering free temporary licenses for QIAGEN CLC Genomics ProSuite. For labs that purchase the QIAseq SARS-CoV-2 Primer Panel Kit (96), we are also offering 25% off subscriptions to QIAGEN CLC Genomics software. Learn more here.
Additionally, our data scientists have expanded upon recent peer-reviewed research to generate relevant SARS-CoV-2 protein networks. This freely available Coronavirus Network Explorer helps you visualize how SARS-CoV-2 proteins interact with human host proteins to disable protective responses and pathways, and explore hypotheses around ways to fight coronavirus.
How can we support your lab?
Stories
-
Suppliers behind the front lines of COVID-19Suppliers find novel ways to motivate while working long hours to up the supply of components necessary for coronavirus testing kits.
-
Ensuring critical deliveries when every minute countsUPS teams up with QIAGEN to deliver coronavirus testing solutions to curb the COVID-19 pandemic.
-
A rapid response to coronavirusQIAGEN is responding as quickly as possible to provide solutions to contain the spread of the coronavirus. -
Is it Influenza – or something else?How QIAstat-Dx, the next generation in syndromic testing, sparked a small revolution in a French hospital.
QIAGEN solutions
-
QIAstat-Dx
The next generation of syndromic insights
Harness the full potential of multiplex syndromic testing and confidently provide clinical insights to patients with the highest level of versatility.
-
QIAGEN Digital Insights
Bioinformatics analysis of SARS-CoV-2 with QIAGEN Digital Insights
To support the efforts of labs sequencing the SARS-CoV-2 virus on the front lines of the COVID-19 pandemic, QIAGEN is offering free temporary licenses to researchers worldwide involved with COVID-19 research and response.
-
QIAcube Connect
Redefining automated sample processing
Fully automate QIAGEN gold-standard spin-column purification procedures with the new QIAcube Connect instrument.
-
EZ1 DSP Virus Kit
Contains all required reagents for automated purification
The EZ1 DSP Virus Kit is ideal for automated, simultaneous purification of viral nucleic acids and bacterial DNA from 1–6 or 1–14 human biological specimens.
-
QIAamp Viral RNA Mini Kit
For isolation of viral RNA from cell-free body fluids
By binding viral RNA to the QIAamp silica membrane, the QIAamp Viral RNA Mini Kit simplifies purification of viral RNA from cell-free body fluids with fast spin-column or vacuum procedures. The procedure can be fully automated.
-
EZ1 Advanced XL
For automated nucleic acid purification
With EZ1 Advanced XL you can fully automate your nucleic acid purification from a wide range of sample types relevant for molecular diagnostics.
*The number of targets/pathogens detected by the QIAstat-Dx Respiratory SARS-CoV-2 Panels is different in different countries.
The QIAstat-Dx Respiratory SARS-CoV-2 Panels are intended for in vitro diagnostic use.
The US version of the QIAstat-Dx Respiratory SARS-CoV-2 Panel is intended for in vitro diagnostic use under Emergency Use Authorization Only. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high complexity and moderate complexity tests.
The QIAstat-Dx Respiratory SARS-CoV-2 Panel has not been FDA cleared or approved;
The QIAstat-Dx Respiratory SARS-CoV-2 Panel has been authorized by FDA under an EUA for use by authorized laboratories;
The QIAstat-Dx Respiratory SARS-CoV-2 Panel has been authorized only for the detection and differentiation of nucleic acid of SARS-CoV-2 from multiple respiratory viral and bacterial organisms; and
The QIAstat-Dx Respiratory SARS-CoV-2 Panel is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.